Objective: The objective of this study was to review the links between ethnicity, serology and clinical expression in systemic lupus erythematosus (SLE) in a single cohort that was followed over a 36-year period. Patients and methods: Patients with SLE treated at the University College London Hospitals (UCLHs) between January 1978 and December 2013 formed the cohort. We assessed the demographic, clinical and serological data. Standard methods were used for laboratory testing. The Student t test and Mann-Whitney U test were used for the continuous variables; the Fisher's exact test was used for the categorical variables. Results: We studied 624 SLE patients: There were 571 women (91.5%), with a mean age at diagnosis of 29.0 AE 6.5 years; and 53 men (8.5%), with a mean age at diagnosis of 29.4 AE 15.3 years. Ethnically, 369 of the patients were European, 100 were Afro-Caribbean, 77 were East Asian, 56 were South Asian and 21 were of mixed ethnicity. The East Asian patients developed the disease at a younger age than the other ethnic groups (p < 0.0001). The Afro-Caribbean patients were less frequently associated with the presence of rash and photosensitivity, and the non-European patients were more likely to have alopecia and renal involvement. The South Asian patients were significantly associated with musculoskeletal and neurological involvement, serositis, Sicca syndrome and hematological features. The Afro-Caribbean patients had the highest prevalence of anti-Smith, anti-RNP, anti-Ro and anti-La antibodies. Anti-IgG anticardiolipin (aCL) antibodies were significantly associated with the non-East Asian groups; and hypocomplementemia was common in the East Asians. Rash, alopecia, mouth ulcers, serositis, neurological, joint and renal involvement were significantly associated with the presence of anti-Smith and anti-RNP antibodies in the Afro-Caribbean group. We also observed an association of joint involvement and the presence of anti-Ro and anti-La antibodies in this group. Conclusions: The East Asian patients developed their SLE disease at a younger age than the other ethnic groups. Cutaneous involvement was more frequent in those who were not Afro-Caribbean. Serositis, joint and neurological involvement were more frequently diagnosed in the South Asian patients. Anti-ENA antibodies were frequently associated with the Afro-Caribbean patients. Lupus (2017) 26, 17-26.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease of complex, incompletely understood etiology, with a wide spectrum of clinical and immunological manifestations. 1, 2 The pathogenesis and expression of the disease is likely to be influenced by genetic, environmental or sociodemographic factors. This multiplicity of factors helps to explain the variability observed in the expression of the disease between individuals and ethnic groups. 2 Ethnic differences may influence the clinical expression of the disease and the presence of autoantibody profiles. 1 Several studies have demonstrated that non-white individuals present at a younger age, have a higher frequency of severe renal disease and ultimately a worse prognosis, when compared with Caucasians. [3] [4] [5] [6] [7] In SLE, the most distinctive laboratory feature is the presence of autoantibodies to nuclear antigens, including dsDNA, histones, RNP and the Sm antigen. 1, 8 Autoantibodies in SLE may be diagnostic and/or markers of disease activity, and may be detected before the diagnosis of the disease. [8] [9] [10] Many studies show substantial ethnic disparities in the burden of SLE, with consequent influence on the severity and final outcome of disease. 11 Earlier studies reported a higher proportion of renal disease (40.5%) and renal failure (15.3%) in black SLE patients, who were also diagnosed at a younger age (34.4 AE 14.9 years), when compared with white patients (18.8%, 4.5% and 41.9 AE 21.3 years, respectively). 11 A recent study of 42,221 SLE patients revealed that SLE was more frequently diagnosed in white (20.17%) and black (24.13%) patients than in Asian (5.18%) patients. In addition, a higher mortality risk was observed in black patients (hazard ratio (HR) ¼ 1.21 (95% CI 1.10-1.33)), compared with whites; and conversely, that the risk was significantly lower among the Asian patients (HR ¼ 0.59 (95% CI 0.40-0.86)), when compared with white patients. A similar result was also observed in patients with lupus nephritis, where the mortality risk was lower in Asian patients compared with white patients. 12 Other differences between ethnic groups include the demonstration that African-American SLE women express higher serum levels of specific Toll-like receptors (TLR-9) and pro-inflammatory cytokines (IL-6 and TNF-a), when compared with European-American women. 13 In addition, metaanalysis studies reveal that the FcyRIIIA-F158 allele, a Fcy receptor subtype, is predisposed to lupus nephritis in Asian patients. 14 Also, higher rates of lupus nephritis-associated autoantibodies have been described in this ethnic group, when compared with White patients. 15 In this study, we sought to take advantage of a relatively large cohort of diverse ethnicity SLE patients who were followed up very carefully over a long period of time (up to 36 years). We have thus been able to make direct comparisons in the same cohort, between four ethnic groups.
Methods and patients

Patients
We performed an audit of all the SLE patients that were followed up in the Rheumatology Department at the University College of London Hospital (UCLH) between January 1978 and December 2013. The demographic, clinical and serological data were collected and reviewed. The study population included a total of 624 patients (571 female and 53 male patients) attending UCLH, whom fulfilled the revised criteria of the American College of Rheumatology (ACR) for SLE. 16 The demographic information collected included gender, ethnicity and age at diagnosis. The information on ethnicity was self-designated and patients were divided according to geographical origin: Patients of mixed origin were excluded from the analysis, as well as patients from the countries of Somalia and Eritrea (based on the difficulty of categorization and the small number of patients).
Methods
The routine laboratory serology results were analyzed by standard methods. From 1978 to 1988, a radioimmunoassay (Amersham, UK) was used in the serial measurement of anti-DNA antibody levels. From April 1988, we used an ELISA (Cambridge Life Sciences, Cambridge, UK). In each case, we regarded twice the upper limit of normal (25 U and 100 U, respectively) recommended by these manufacturers as a raised level. Three raised levels were required or a positive Crithidia lucida test, before a patient was recorded as DNA antibody positive. Patients had re-assessments approximately every 5 years for antibodies to Ro/ SSA, La/SSB, Sm and RNP (originally by counterimmunoelectrophoresis; and since 1988, by ELISA (Shield Diagnostics, Dundee, UK)); as well as repeated Coombs tests, rheumatoid factor assessments and lupus anti-coagulant (LA) testing. The assays used are described in detail elsewhere. 17, 18 For the long-term follow-up serological part of this study, we used the routine DNA antibody and serum C3 results (measured by laser nephelometer, using UK approved standards with normal range 0.75-1.75 ug/ml; three reduced levels were required before the patient was regarded as having low C3). The C3 levels were expressed as a proportion of the lower limit of normal and (because of the change in assay) the DNA binding antibodies as a fraction of the upper limit of normal (i.e. irrespective of the assay).
Solid-phase assays for anti-Ro/SSA, 17, 19 anti-La/ SSB, 17, 20 anti-U1 RNP and anti-Sm 17 were performed using affinity-purified antigens prepared from calf thymus tissue extract. Solid-phase assays for anti-ribosomal P and Western blotting were performed as previously described. 17, 21 RF was detected using the latex fixation method (Becton Dickinson, Sparks, Maryland, USA). Titers of !1:80 were considered positive. The presence of antinuclear antibodies (ANA) was tested using dilutions of serum on a human epithelial cell line (HEp-2). Fluorescence at a titer !1:80 was considered positive. IgG and IgM anti-cardiolipin tests were done by commercial ELISA; and LA by the dilute Russell's viper venom time, and the anti-thyroid antibody tests by immunofluorescence.
The autoantibody profiles were obtained at or shortly after diagnosis. As previously published, 22 17% of the patients with positive ANA in our group became negative, over a decade. In addition, high dsDNA antibody levels likewise tended to normalize over time; whereas the ENA antibody profiles presented some fluctuation; but overall, most of these patients tended to keep the same patterns over time. 23 The disease manifestations of the study group were collected at diagnosis, with the new clinical features being cumulatively added over time.
Statistical analysis
Descriptive results are presented as frequencies (%), mean or SD. Comparisons between continuous variables were made using the Student t test and the Mann-Whitney U test. Fisher's exact test was used for categorical variables, when it was appropriate. Values of p < 0.05 (2-tailed) were considered significant.
Results
A total of 624 SLE patients were studied, 571 were female patients (91.5%), with a mean age at diagnosis of 29.0 AE 12.3 years (7-77 years); and 53 were male patients (8.5%), with a mean age at diagnosis of 29.4 AE 15.3 years (1-63 years). No significant differences were found between patient gender and the age at diagnosis (t-value ¼ 0.256; p ¼ 0.798).
There were 369 SLE patients who were European (59.1%), 100 SLE patients who were Afro-Caribbean (16.0%), 77 SLE patients who were East Asian (12.3%) and 56 SLE patients who were South Asian (9.0%). We had 20 patients who were of mixed ethnicity and in one patient, that information was missing.
Those of female gender were more frequently affected in all ethnic groups, with no significant difference found between the genders in the different ethnic groups (p ¼ 0.324-1.00) ( Table 1) .
The East Asian patients developed their SLE disease at a younger age than the European, Afro-Caribbean and South Asian patients (t-value ¼ 4.154-5.597; p < 0.0001) ( Table 1) . No statistically significant differences were observed in the age at diagnosis between genders.
The clinical profile analysis of the ethnic groups is described in Table 2 , and shows a significant association of musculoskeletal involvement in the South Asian group, presented in all patients, when compared with the other ethnic groups (100% versus 81.0% to 92.9%, respectively; p ¼ 0.0002-0.039); and had been a less frequent clinical feature in the Afro-Caribbean patients (81.0% versus 92.2% to 100%, respectively; p ¼ 0.0002-0.049).
The European group was significantly associated with the presence of:
. rash (70.9%, compared with 46.9% in Afro-Caribbean and 63.6% in East Asian patients, respectively; p < 0.0001) and In contrast, these patients were less likely to have alopecia than the other ethnic groups (16.0% versus 28.6% to 38.0%, respectively; p ¼ 0.0001-0.014). Afro-Caribbean patients complained less frequently of photosensitivity, when compared with the other ethnic groups (8.2% versus 37.7% to 49.2%, respectively; p < 0.0001).
Notably, renal involvement was less frequently diagnosed in the European patients than in Afro-Caribbean and East Asian patients (24.1% versus 36.4% and 49.4%, respectively; p ¼ 0.0001-0.021).
Interestingly, South Asian patients developed more frequently:
. The Afro-Caribbean group had less frequent thrombocytopenia, when compared with the European and South Asian patients (7.1% versus 15.3% and 21.4%, respectively; p ¼ 0.012-0.032).
No other statistically significant differences were observed in the other clinical categories. After analyzing the serological data, the frequency of ANA and anti-dsDNA antibodies was similar in all groups (Table 3) , with a mean variation ranging between 89.0-96.4% and 61.6-67.6%, respectively.
The Afro-Caribbean patients had the greatest prevalence (one-third of the patients) of anti-Smith antibodies, when compared with the other ethnic groups (37.5% versus 9.5% to 17.6%, respectively; p ¼ 0.0001-0.006). In addition, in comparison with European patients, the Afro-Caribbean group had a higher prevalence of anti-Ro (53.1% versus 32.2%, respectively; If in a horizontal line of the table, none of the items is shown in bold, no statistically significant differences were observed for this clinical manifestation among groups, and the lower and higher p values are presented. If only one group (one item) is selected in bold, a statistically significant difference was observed between that group and the other three ethnic groups, and only the significant p values (the lower and higher) are presented. If two groups are selected in bold, a statistically significant difference was observed between those two ethnic groups, and only that p value is presented. If three groups are selected in bold, a statistically significant difference was observed between the group who presents the lowest or higher value, compared to the two other ethnic groups, and the two significant p values are presented. If the four ethnic groups are selected in bold, a statistically significant difference was observed between the group with the lowest value compared to the three other ethnic groups and between the group which has the higher value, compared to the three other ethnic groups, and only the significant p values (the lower and higher) are presented. SLE: systemic lupus erythematosus p ¼ 0.0002) and anti-La (20.8% versus 11.7%, respectively; p ¼ 0.028) antibodies. The Afro-Caribbean group also had the higher prevalence of anti-RNP antibodies (53.1% compared with 20.3% in the European, 28.6% in the South Asian and 34.7% in the East Asian patients, respectively; p ¼ 0.0001-0.012). There was less frequent expression in the European patients (20.3% compared with 34.7% in East Asian and 53.1% in Afro-Caribbean patients, respectively; p ¼ 0.0001-0.013).
In the European group, hypocomplementemia (low C3) was a less common feature, occurring in 38.9% of the patients (compared with 65.8% of the East Asian patients and 50.5% of the Afro-Caribbean patients, respectively; p ¼ 0.0001-0.039).
Anti-IgG anticardiolipin (aCL) antibodies were detected less frequently in the East Asian patients, when compared with the European and South Asian patients (7.9% versus 21.8% and 25.0%, respectively; p ¼ 0.004-0.012).
The analysis of clinical and serological links between the ethnic groups ( ) is selected in bold, a statistically significant difference was observed between that group and the other three ethnic groups, and only the significant p values (the lower and higher) are presented. If two groups are selected in bold, a statistically significant difference was observed between those two ethnic groups, and only that p value is shown. If three groups are selected in bold, a statistically significant difference was observed between the group with the lowest or higher value compared to the two other ethnic groups, and the two significant p values are presented. If the four ethnic groups are selected in bold, a statistically significant difference was observed between the group that had the lowest value compared to the three other ethnic groups and between the group with the higher value compared to the three other ethnic groups, and only the significant p values (the lower and higher) are presented. aCL: anticardiolipin; ANA: antinuclear antibodies; dsDNA: double-stranded DNA; RF: rheumatoid factor; SLE: systemic lupus erythematosus ) is selected in bold, a statistically significant difference was observed between that group and the other three ethnic groups, and only the significant p values (the lower and higher) are presented. If two groups are selected in bold, a statistically significant difference was observed between those two ethnic groups, and only that p value is presented. If three groups are selected in bold, a statistically significant difference was observed between the group that had the lowest or higher value, compared to the two other ethnic groups, and the two significant p values are shown. If the four ethnic groups are selected in bold, a statistically significant difference was observed between the group with the lowest value, compared to the three other ethnic groups and between the group with the higher value compared to the three other ethnic groups, and only the significant p values (the lower and higher) are presented. In the East Asian patients, hypocomplementemia was a common presentation that has been associated with:
. cutaneous symptoms such as rash, 
Discussion
We studied a relatively large number of SLE patients followed carefully over a long period of time, using broadly similar assays throughout, to review ethnic diversity in SLE disease. Although there have been other studies of this nature, they were mostly multi-site studies of much shorter duration, often using different assays to measure for example, dsDNA antibodies, and usually involving just two or three ethnic groups. As expected, female individuals were more affected by SLE 24 in each ethnic group. In our study, the European, South Asian and Afro-Caribbean patients developed the disease later than the East Asian group. This result was consistent with previous reports (e.g. from Leicester, UK) where a younger age at diagnosis was observed in Asian patients (24 AE 6 years) compared with the white patients (31 AE 5 years). 25 Interestingly, and unlike our experience, the previous reports found that African-American female patients with SLE had a younger mean age at diagnosis, compared with white female patients. 26 Skin lesions in SLE are frequent (about 75% of patients) and often polymorphic. 27, 28 In the present study, skin lesions (namely rash and photosensitivity) were less frequent in the Afro-Caribbean group. These features that had been observed in previous reports, 7, [29] [30] [31] were perhaps less easily recognized in this group. 32 A negative association with renal involvement was observed in the European patients, when compared with the other ethnic groups, a result consistent with previous reports. 6, 29, [33] [34] [35] In a systematic review of SLE in Asia, higher rates of renal involvement were described in Asian patients (21-65% at diagnosis and 40-82% at follow-up), when compared with white patients. 6, 33 Renal disease was also more common in the black SLE patients in our study, as had previously been reported. 7, 29, 34 All of our South Asian patients had musculoskeletal involvement (100%), a feature less frequent in the other ethnic groups. Interestingly, Jasmin et al. 35 showed that arthritis is a common clinical manifestation (52.3%) in the multi-ethnic Malaysian population, with Indian patients having a higher risk of arthritis compared with the Malay and Chinese Malaysian patients.
ANA and anti-dsDNA antibodies are the most frequent autoantibodies detected in all ethnic groups. Analysis of individual autoantibody specificities in the anti-ENA spectrum revealed significant differences among ethnic groups. Reports in Afro-Caribbean SLE patients indicate that anti-Sm, anti-RNP and anti-Ro are more prevalent than in those with European ancestry. 30, 31, 34 As previously observed, [29] [30] [31] 34, 36 the Afro-Caribbean SLE patients in our study had the greatest prevalence of anti-Sm antibodies (37.5%), which were much less common in the other groups (European 9.5%, East Asian 17.6% and South Asian 14.3%).
Curiously, Li et al. 37 studied a Chinese SLE population of 2170 individuals and observed a positivity of 44.1% for anti-phospholipid antibodies (aPL), aCL, anti-B2 glucoprotein I antibody and LA, a significantly high number when compared with our group of East Asian patients, where the frequency of anti-IgG aCL, anti-IgM aCL and LA were of 7.9%, 6.6% and 13% (with a total of 24.7% or 19/77; p ¼ 0.0007), respectively, and a significant association between our non-East Asian SLE patients with positivity for anti-IgG aCL antibodies and several clinical features (namely: rash, photosensitivity, musculoskeletal and renal involvement, serositis and lymphopenia). In contrast, Li et al. found an association between aPL antibodies and hematological involvement, interstitial lung disease and a lower prevalence of oral ulcerations (p < 0.05), 37 a result not consistent with our findings.
In this study, we observed that the Afro-Caribbean SLE patients with kidney involvement have higher positivity for ENA antibodies (anti-Sm and anti-RNP), as reported previously. 1 In addition, in this ethnic group we observed a significant association between anti-Ro positivity and the presence of cutaneous manifestations (skin rash), as previously described in the literature. 38, 39 A previous study shows that Asian ethnicity is significantly associated with a more clinically severe SLE, with patients being more likely to have renal disease (OR 2.9; 95% CI 1.4-5.98; p ¼ 0.004), a significantly higher proportion of autoantibody positivity to anti-RNP and anti-Sm, and an increased likelihood of hypocomplementemia, 40 which is in agreement with our findings.
It is important to mention that the apparent differences that we observed in phenotypic expression, severity and even frequency of SLE between the different ethnic groups may be due to genetic or environmental (including cultural) factors, or a combination of both. 41 As the LUMINA (stands for lupus in minorities, nature versus nurture) study shows, 42 rather than ethnicity per se, a lower income and the patients' socioeconomic status are independent risk factors for SLE disease progression and outcome. In parallel, a study 43 has also revealed that income (but not ethnicity nor education level) is strongly associated with renal damage in a SLE cohort of patients. Unfortunately, in the US studies it is hard to disentangle genetic and socio-economic factors; however, a study from the UK (where healthcare is free at the point of access to the system) clearly shows that renal disease and renal failure are much more common in the black population (compared with the Caucasian group), strongly suggesting that genetic factors are highly significant in determining clinical outcome. 44 Much of what is discussed in the literature has been through the use of self-reported ethnicity in genetic and epidemiologic studies, which may be seen as an important bias and could lead to misleading information. 5, 45 Of major importance, as demonstrated when examining ancestry-related informative markers, is that it is clear that no homogeneous racial groups exist within the human race. 46 
